Attended Mark G Kris lecture on Lung Cancer (KRIS IS FROM MSKCC)
Now genetic sequencing is important
Prescribe the following
1) EGFR-------------ERLOTINIB, GEFITINIB
2) ALK-----------------CRIZOTINIB
3) HER-2--------------HERCEPTIN, LAPATINIB
4) BRAF -------------------VEMURAFENIB
5) ROS-1-----------------CRIZOTINIB (AGAIN)
6) RET--------------------------VANDETANIB (CABOZANTINIB)
7)MET------------------------CRIZOTINIB (AGAIN)
NICE THE PRESCRIPTION SPELLING OUT ONLY THE GENE SEQUENCING, AND LET YOUR PHARMACIST DO THE REST.
QUESTION: COULD THESE DRIVER GENE ABNORMALITIES BE THE SAME IN TRIPLE NEGATIVE BREAST CANCER?
A blog about research, awareness, prevention, treatment and survivorship of Breast Cancer and all cancers, including targeted scientific research and a grassroots approach to increase screening for cancer, especially in the low income and under-insured population of El Paso, Texas, with a view to expand this new health care model to many other 'minority' populations across the United States and beyond
Showing posts with label gefitinib. Show all posts
Showing posts with label gefitinib. Show all posts
Thursday, December 13, 2012
Labels:
ALK,
BRAF,
cabozantine,
crizotinib,
crozotinib,
EGFR,
erlotinib,
gefitinib,
HER-2,
herceptin,
KRIS,
lapatinib,
lung cancer,
Met,
RET,
ROS-1,
vandetanib,
vemurafenib
Subscribe to:
Posts (Atom)